NDANASALSPRAY, METERED
Approved
Feb 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNAREL (nafarelin acetate) is a synthetic gonadotropin-releasing hormone (GnRH) agonist administered as a metered nasal spray. It suppresses pituitary gonadotropin secretion, leading to decreased sex hormone production. The drug is indicated for endometriosis and precocious puberty in patients requiring hormonal modulation.
$0.204MPart D
LOE ApproachingWith LOE approaching and minimal current market spend, the SYNAREL team is likely optimizing legacy franchise performance and managing transition planning rather than driving growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYNAREL positions offer limited career growth due to its LOE-approaching status and minimal job openings (0 linked roles). Roles on this franchise focus on managing decline, defending market share against generics, and optimizing reimbursement rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on SYNAREL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.